Currently out of the existing stock ratings of Mike Matson, 790 are a BUY (83.6%), 150 are a HOLD (15.87%), 5 are a SELL (0.53%).

Mike Matson

Work Performance Price Targets & Ratings Chart

Analyst Mike Matson, currently employed at NEEDHAM, carries an average stock price target met ratio of 60.59% that have a potential upside of 27.85% achieved within 324 days.

Mike Matson’s has documented 1,727 price targets and ratings displayed on 50 stocks. The coverage is on Healthcare, Technology, Financial Services, Industrials, Utilities sectors.

Most recent stock forecast was given on MDT, Medtronic PLC at 10-Mar-2026.

Wall Street Analyst Mike Matson

Analyst best performing recommendations are on PSNL (PERSONALIS).
The best stock recommendation documented was for ATRC (ATRICURE) at 4/27/2021. The price target of $74 was fulfilled within 2 days with a profit of $9.09 (14%) receiving and performance score of 70.02.

Average potential price target upside

ATRC AtriCure AXNX Axonics Modulation Technologies CNMD CONMED FNA Paragon 28 GMED Globus Medical HAE Haemonetics HRC Hill-Rom Holdings INMD InMode Ltd KIDS Orthopediatrics Corp LIVN LivaNova PLC LUCD Lucid Diagnostics MDT Medtronic PLC MMSI Merit Medical Systems NUVA NuVasive RMD ResMed SRDX SurModics SYK Stryker TFX Teleflex VCYT Veracyte ZBH Zimmer Biomet Holdings BSX Boston Scientific Corp CSII Cardiovascular Systems GNMK GenMark Diagnostics HOLX Hologic INGN Inogen MDXG MiMedx Group NEO NeoGenomics OCX OncoCyte Corp CRY CryoLife STE STERIS plc WMGI Wright Medical Group N.V AORT Artivion PSNL Personalis PEN Penumbra MASI Masimo CMD Cantel Medical Corp IVC Invacare SWAV Shockwave Medical ENOV Enovis Corp NARI Inari Medical  AAPL Apple ICUI ICU Medical TMDX TransMedics Group ESTA Establishment Labs Holdings AX Axos Financial BEAT Heartbeam CR Crane Company FN Fabrinet NEON SR Spire

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 24-Feb-2021

$53

$24.12 (83.52%)

$64

1 months 11 days ago
(18-Feb-2026)

2/19 (10.53%)

$20.74 (64.29%)

36

Hold Since 18-Feb-2026

$45

1 months 11 days ago
(18-Feb-2026)

10/11 (90.91%)

$5.41 (13.67%)

113

Buy Since 28-Apr-2021

$54

$25.12 (86.98%)

$53

1 months 11 days ago
(18-Feb-2026)

5/10 (50%)

$21.74 (67.39%)

98

Buy Since 06-Oct-2015

$55

$26.12 (90.44%)

$58

1 months 11 days ago
(18-Feb-2026)

6/17 (35.29%)

$22.74 (70.49%)

277

Buy Since 23-Mar-2015

$45

$16.12 (55.82%)

$45

1 months 17 days ago
(12-Feb-2026)

23/49 (46.94%)

$13.2 (41.51%)

179

Show more analysts

Please expand the browser size to see the chart

Which stock is Mike Matson is most bullish on?

Potential upside of $126.56 has been obtained for SYK (STRYKER)

Which stock is Mike Matson is most reserved on?

Potential downside of -$0 has been obtained for ZBH (ZIMMER BIOMET HOLDINGS)

What Year was the first public recommendation made by Mike Matson?

On 2013

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?